Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T19:58:06.678Z.
Calculation as of: 2026-10-06T19:58:06.678Z.
Quote observation: 2026-10-06T19:54:48.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a49bf55b95e7accb53c24ef9933cb867312288378507dab28e57e4bc75072383
PE RATIO
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| InspireMD, Inc. (NSPR) | $24.64M | N/A | N/A | N/A | N/A |
| Atossa Therapeutics, Inc. (ATOS)vs › | $24.59M | N/A | N/A | N/A | N/A |
| ABVC BioPharma, Inc. (ABVC)vs › | $24.91M | N/A | 2021.12 | 2021.12 | 2021.12 |
| Kyntra Bio, Inc. (KYNB)vs › | $23.92M | N/A | 2502.34 | 2502.34 | 2502.34 |
| TherapeuticsMD, Inc. (TXMD)vs › | $23.26M | N/A | 89.23 | 89.23 | 89.23 |
| iTonic Holdings Ltd. (ITOC)vs › | $26.05M | N/A | N/A | N/A | N/A |
| Rein Therapeutics Inc. (RNTX)vs › | $22.95M | N/A | N/A | N/A | N/A |
| LeonaBio, Inc. (LONA)vs › | $22.50M | N/A | N/A | N/A | N/A |
| Modular Medical, Inc. (MODD)vs › | $22.25M | N/A | N/A | N/A | N/A |
| Aytu BioPharma, Inc. (AYTU)vs › | $22.00M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$0.53
Forward EPS (Est.)
$-0.61
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
